Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Tipo de documento: | Tese |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFS |
Texto Completo: | http://ri.ufs.br/jspui/handle/riufs/16817 |
Resumo: | Introduction. In the last decades, health expenditures, mainly in the elderly population, have been a great concern for health systems around the world, which have a direct economic impact with population aging. Economic evaluations provide information to stakeholders and decision makers so that resources are used efficiently. Therefore, the presence of the pharmacist may avoid some unnecessary expenses, as well as improve health outcomes. So, this study carried out a scoping review in order to identify which indicators are used to assess economic and pharmacoeconomic outcomes in elderly patients with cardiovascular risk diseases and, based on these indicators, identify which services are considered more likely to reduce costs in health. Objective. Identify which indicators are used to assess economic and pharmacoeconomic outcomes in elderly patients with chronic diseases that contribute to cardiovascular risk treated by pharmacists in an outpatient setting. Method. This study was divided into two steps. In the first step, a scoping review was carried out to understand the financial burden on elderly patients with chronic diseases that contribute to cardiovascular risk treated by pharmacists on an outpatient basis. In the second step, another scoping review was performed with the objective of identifying the indicators used in pharmacoeconomic studies in elderly patients with chronic diseases that contribute to cardiovascular risk treated by pharmacists on an outpatient basis. In order to understand which economic indicators are more related to clinical and humanistic indicators. Results. In the first step, 13 articles were included. Most studies were specific to patients with diabetes. The most used indicators were The most used indicators were pharmacotherapeutic monitoring, identification and prevention of drug-related problems and health education. The average cost per patient and the cost of their medications were the most reported financial indicators. In the second step, twelve articles, published in English in four continents: America, Asia, Oceania, and Europe, were included. Most studies have been conducted in the United States. For the cost-effectiveness analysis, the following clinical indicators were used: glycated hemoglobin, cholesterol levels, and blood pressure. For the cost-utility analysis, the quality-adjusted life years (QALY) was considered, and for the cost-benefit analysis, the additional financial benefit for clinical improvement was calculated. The cost category addressed in most articles was direct medical cost, with labor cost and cost per intervention associated with reduction of clinical measures being the most reported among the studies. Conclusion. The cost indicators and outcome measures available in the literature were raised in this review and, in general, the clinical benefit of the service outweighed the cost of intervention, especially when associated with more complex pharmaceutical clinical services. In this way, it is hoped that the indicators gathered will help towards a more comprehensive assessment of the financial burden related to the disease and help guide future policies in this area. |
id |
UFS-2_3041ea28e1ed1305f8a7b309c0e45079 |
---|---|
oai_identifier_str |
oai:ufs.br:riufs/16817 |
network_acronym_str |
UFS-2 |
network_name_str |
Repositório Institucional da UFS |
repository_id_str |
|
spelling |
Carvalho, Gabriela Andrade ConradoLyra Júnior, Divaldo Pereira de2022-11-24T14:23:31Z2022-11-24T14:23:31Z2022CARVALHO, Gabriela Andrade Conrado. Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório. 2022. 104 f. Tese (doutorado em Ciências da Saúde) – Universidade Federal de Sergipe, Aracaju, 2022.http://ri.ufs.br/jspui/handle/riufs/16817Introduction. In the last decades, health expenditures, mainly in the elderly population, have been a great concern for health systems around the world, which have a direct economic impact with population aging. Economic evaluations provide information to stakeholders and decision makers so that resources are used efficiently. Therefore, the presence of the pharmacist may avoid some unnecessary expenses, as well as improve health outcomes. So, this study carried out a scoping review in order to identify which indicators are used to assess economic and pharmacoeconomic outcomes in elderly patients with cardiovascular risk diseases and, based on these indicators, identify which services are considered more likely to reduce costs in health. Objective. Identify which indicators are used to assess economic and pharmacoeconomic outcomes in elderly patients with chronic diseases that contribute to cardiovascular risk treated by pharmacists in an outpatient setting. Method. This study was divided into two steps. In the first step, a scoping review was carried out to understand the financial burden on elderly patients with chronic diseases that contribute to cardiovascular risk treated by pharmacists on an outpatient basis. In the second step, another scoping review was performed with the objective of identifying the indicators used in pharmacoeconomic studies in elderly patients with chronic diseases that contribute to cardiovascular risk treated by pharmacists on an outpatient basis. In order to understand which economic indicators are more related to clinical and humanistic indicators. Results. In the first step, 13 articles were included. Most studies were specific to patients with diabetes. The most used indicators were The most used indicators were pharmacotherapeutic monitoring, identification and prevention of drug-related problems and health education. The average cost per patient and the cost of their medications were the most reported financial indicators. In the second step, twelve articles, published in English in four continents: America, Asia, Oceania, and Europe, were included. Most studies have been conducted in the United States. For the cost-effectiveness analysis, the following clinical indicators were used: glycated hemoglobin, cholesterol levels, and blood pressure. For the cost-utility analysis, the quality-adjusted life years (QALY) was considered, and for the cost-benefit analysis, the additional financial benefit for clinical improvement was calculated. The cost category addressed in most articles was direct medical cost, with labor cost and cost per intervention associated with reduction of clinical measures being the most reported among the studies. Conclusion. The cost indicators and outcome measures available in the literature were raised in this review and, in general, the clinical benefit of the service outweighed the cost of intervention, especially when associated with more complex pharmaceutical clinical services. In this way, it is hoped that the indicators gathered will help towards a more comprehensive assessment of the financial burden related to the disease and help guide future policies in this area.Introdução. Nas últimas décadas os gastos com saúde, principalmente, na população idosa têm gerado grande preocupação para os sistemas de saúde ao redor do mundo, que já que sofrem impacto econômico direto com o envelhecimento populacional. As avaliações econômicas fornecem informações aos gestores e tomadores de decisão, para que o destino dos recursos seja utilizado de forma eficiente. Diante disso, a presença do farmacêutico pode evitar alguns gastos desnecessários, bem como melhorar os desfechos em saúde. Para isso, esse estudo fez uma scoping review, a fim de identificar quais os indicadores utilizados para avaliar desfechos econômicos e farmacoeconômicos em pacientes com doenças de risco cardiovasculares e com base nesses indicadores, identificar quais serviços são considerados mais propensos à redução de gastos em saúde. Objetivo. Identificar quais os indicadores utilizados para avaliar desfechos econômicos e farmacoeconômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório. Método. Este estudo foi dividido em duas etapas. Na primeira etapa, foi realizada uma scoping review para compreender o ônus financeiro em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório. Na segunda etapa, foi realizada outra scoping review com o objetivo de identificar os indicadores utilizados em estudos farmacoeconômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório. A fim de compreender quais indicadores econômicos estão mais relacionados com os indicadores clínicos e humanísticos. Resultados. Na primeira etapa, 13 artigos foram incluídos. A maioria dos estudos foi específica para pacientes com diabetes. Os indicadores mais utilizados foram o acompanhamento farmacoterapêutico, identificação e prevenção de PRMs e educação em saúde. O custo médio por paciente e o custo dos seus medicamentos, foram os indicadores financeiros mais relatados. Na segunda etapa, 12 artigos foram incluídos, a análise de custo-efetividade foi a mais relatada e o principal indicador não-financeiro foi a hemoglobina glicada. O custo de mão-de-obra, custo por intervenção associado a redução de medidas clínicas foram as mais relatadas entre os estudos. Conclusão. A revisão evidenciou que a redução de custos foi associada às intervenções farmacêuticas e os principais indicadores estão relacionados aos serviços farmacêuticos de maior complexidade, que é o acompanhamento farmacoterapêutico, associado com a educação em saúde.AracajuporCiências da saúdeFarmacoeconomiaFarmacêuticoAvaliação econômica em saúdeDoenças crônicasHealth SciencesPharmacoeconomicsPharmaceuticalEconomic health assessmentChronic diseasesCIENCIAS DA SAUDEIndicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatórioIndicators used to evaluate economic outcomes in patients with chronic diseases contributing to cardiovascular risk seen by pharmaceuticals in outdoorsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisPós-Graduação em Ciências da SaúdeUniversidade Federal de Sergipereponame:Repositório Institucional da UFSinstname:Universidade Federal de Sergipe (UFS)instacron:UFSinfo:eu-repo/semantics/openAccessORIGINALGABRIELA_ANDRADE_CONRADO_CARVALHO.pdfGABRIELA_ANDRADE_CONRADO_CARVALHO.pdfapplication/pdf6819073https://ri.ufs.br/jspui/bitstream/riufs/16817/2/GABRIELA_ANDRADE_CONRADO_CARVALHO.pdf46ebe5e89c5981e8af6afd0395180a3cMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81475https://ri.ufs.br/jspui/bitstream/riufs/16817/1/license.txt098cbbf65c2c15e1fb2e49c5d306a44cMD51TEXTGABRIELA_ANDRADE_CONRADO_CARVALHO.pdf.txtGABRIELA_ANDRADE_CONRADO_CARVALHO.pdf.txtExtracted texttext/plain147696https://ri.ufs.br/jspui/bitstream/riufs/16817/3/GABRIELA_ANDRADE_CONRADO_CARVALHO.pdf.txt3e1d7ba27b38bc5e9fe54eb03b47cec0MD53THUMBNAILGABRIELA_ANDRADE_CONRADO_CARVALHO.pdf.jpgGABRIELA_ANDRADE_CONRADO_CARVALHO.pdf.jpgGenerated Thumbnailimage/jpeg1285https://ri.ufs.br/jspui/bitstream/riufs/16817/4/GABRIELA_ANDRADE_CONRADO_CARVALHO.pdf.jpg6b02e3839814016204a2d344f2bbbd41MD54riufs/168172022-11-28 12:00:38.366oai:ufs.br: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Repositório InstitucionalPUBhttps://ri.ufs.br/oai/requestrepositorio@academico.ufs.bropendoar:2022-11-28T15:00:38Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)false |
dc.title.pt_BR.fl_str_mv |
Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório |
dc.title.alternative.eng.fl_str_mv |
Indicators used to evaluate economic outcomes in patients with chronic diseases contributing to cardiovascular risk seen by pharmaceuticals in outdoors |
title |
Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório |
spellingShingle |
Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório Carvalho, Gabriela Andrade Conrado Ciências da saúde Farmacoeconomia Farmacêutico Avaliação econômica em saúde Doenças crônicas Health Sciences Pharmacoeconomics Pharmaceutical Economic health assessment Chronic diseases CIENCIAS DA SAUDE |
title_short |
Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório |
title_full |
Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório |
title_fullStr |
Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório |
title_full_unstemmed |
Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório |
title_sort |
Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório |
author |
Carvalho, Gabriela Andrade Conrado |
author_facet |
Carvalho, Gabriela Andrade Conrado |
author_role |
author |
dc.contributor.author.fl_str_mv |
Carvalho, Gabriela Andrade Conrado |
dc.contributor.advisor1.fl_str_mv |
Lyra Júnior, Divaldo Pereira de |
contributor_str_mv |
Lyra Júnior, Divaldo Pereira de |
dc.subject.por.fl_str_mv |
Ciências da saúde Farmacoeconomia Farmacêutico Avaliação econômica em saúde Doenças crônicas |
topic |
Ciências da saúde Farmacoeconomia Farmacêutico Avaliação econômica em saúde Doenças crônicas Health Sciences Pharmacoeconomics Pharmaceutical Economic health assessment Chronic diseases CIENCIAS DA SAUDE |
dc.subject.eng.fl_str_mv |
Health Sciences Pharmacoeconomics Pharmaceutical Economic health assessment Chronic diseases |
dc.subject.cnpq.fl_str_mv |
CIENCIAS DA SAUDE |
description |
Introduction. In the last decades, health expenditures, mainly in the elderly population, have been a great concern for health systems around the world, which have a direct economic impact with population aging. Economic evaluations provide information to stakeholders and decision makers so that resources are used efficiently. Therefore, the presence of the pharmacist may avoid some unnecessary expenses, as well as improve health outcomes. So, this study carried out a scoping review in order to identify which indicators are used to assess economic and pharmacoeconomic outcomes in elderly patients with cardiovascular risk diseases and, based on these indicators, identify which services are considered more likely to reduce costs in health. Objective. Identify which indicators are used to assess economic and pharmacoeconomic outcomes in elderly patients with chronic diseases that contribute to cardiovascular risk treated by pharmacists in an outpatient setting. Method. This study was divided into two steps. In the first step, a scoping review was carried out to understand the financial burden on elderly patients with chronic diseases that contribute to cardiovascular risk treated by pharmacists on an outpatient basis. In the second step, another scoping review was performed with the objective of identifying the indicators used in pharmacoeconomic studies in elderly patients with chronic diseases that contribute to cardiovascular risk treated by pharmacists on an outpatient basis. In order to understand which economic indicators are more related to clinical and humanistic indicators. Results. In the first step, 13 articles were included. Most studies were specific to patients with diabetes. The most used indicators were The most used indicators were pharmacotherapeutic monitoring, identification and prevention of drug-related problems and health education. The average cost per patient and the cost of their medications were the most reported financial indicators. In the second step, twelve articles, published in English in four continents: America, Asia, Oceania, and Europe, were included. Most studies have been conducted in the United States. For the cost-effectiveness analysis, the following clinical indicators were used: glycated hemoglobin, cholesterol levels, and blood pressure. For the cost-utility analysis, the quality-adjusted life years (QALY) was considered, and for the cost-benefit analysis, the additional financial benefit for clinical improvement was calculated. The cost category addressed in most articles was direct medical cost, with labor cost and cost per intervention associated with reduction of clinical measures being the most reported among the studies. Conclusion. The cost indicators and outcome measures available in the literature were raised in this review and, in general, the clinical benefit of the service outweighed the cost of intervention, especially when associated with more complex pharmaceutical clinical services. In this way, it is hoped that the indicators gathered will help towards a more comprehensive assessment of the financial burden related to the disease and help guide future policies in this area. |
publishDate |
2022 |
dc.date.accessioned.fl_str_mv |
2022-11-24T14:23:31Z |
dc.date.available.fl_str_mv |
2022-11-24T14:23:31Z |
dc.date.issued.fl_str_mv |
2022 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
format |
doctoralThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
CARVALHO, Gabriela Andrade Conrado. Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório. 2022. 104 f. Tese (doutorado em Ciências da Saúde) – Universidade Federal de Sergipe, Aracaju, 2022. |
dc.identifier.uri.fl_str_mv |
http://ri.ufs.br/jspui/handle/riufs/16817 |
identifier_str_mv |
CARVALHO, Gabriela Andrade Conrado. Indicadores utilizados para avaliar desfechos econômicos em pacientes com doenças crônicas que contribuem para o risco cardiovascular atendidos por farmacêuticos em ambulatório. 2022. 104 f. Tese (doutorado em Ciências da Saúde) – Universidade Federal de Sergipe, Aracaju, 2022. |
url |
http://ri.ufs.br/jspui/handle/riufs/16817 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.program.fl_str_mv |
Pós-Graduação em Ciências da Saúde |
dc.publisher.initials.fl_str_mv |
Universidade Federal de Sergipe |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFS instname:Universidade Federal de Sergipe (UFS) instacron:UFS |
instname_str |
Universidade Federal de Sergipe (UFS) |
instacron_str |
UFS |
institution |
UFS |
reponame_str |
Repositório Institucional da UFS |
collection |
Repositório Institucional da UFS |
bitstream.url.fl_str_mv |
https://ri.ufs.br/jspui/bitstream/riufs/16817/2/GABRIELA_ANDRADE_CONRADO_CARVALHO.pdf https://ri.ufs.br/jspui/bitstream/riufs/16817/1/license.txt https://ri.ufs.br/jspui/bitstream/riufs/16817/3/GABRIELA_ANDRADE_CONRADO_CARVALHO.pdf.txt https://ri.ufs.br/jspui/bitstream/riufs/16817/4/GABRIELA_ANDRADE_CONRADO_CARVALHO.pdf.jpg |
bitstream.checksum.fl_str_mv |
46ebe5e89c5981e8af6afd0395180a3c 098cbbf65c2c15e1fb2e49c5d306a44c 3e1d7ba27b38bc5e9fe54eb03b47cec0 6b02e3839814016204a2d344f2bbbd41 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS) |
repository.mail.fl_str_mv |
repositorio@academico.ufs.br |
_version_ |
1802110694338854912 |